Cardiovascular gene therapy is becoming a clinical reality due to improved vectors, delivery systems and careful experimental validation studies. Nearly all cardiovascular diseases are amenable to gene therapy, but the optimal combination of vector, delivery system and therapeutic gene is likely to be unique to each application. Currently, the most efficient vectors available are replication-defective adenoviral vectors, but transgene expression is limited in time due to a strong immune response. Conversely, non-viral vectors or plasmid DNA may be used safely but have very limited efficiency. Percutaneous, catheter-based delivery is feasible for most applications. The ultimate issues that will decide of the future of gene therapy are safety of the transfer and delivery techniques as well as costreffectiveness comparisons with alternative therapies, including local delivery of drugs, proteins andror mechanical devices. q 1997 Elsevier Science B.V.
Introduction
Atherosclerosis and its complications represent the first w x cause of mortality and morbidity in the western world 1 . Major advances have been made in the treatment and prevention of symptomatic atherosclerosis. Improved understanding of the pathophysiology of atherosclerosis and w x its complications 2 , as well as spectacular advances in the w x molecular biology of the vascular wall 3,4 may open new perspectives for treatment based upon local delivery of genetic material designed to modify the atherosclerotic w x plaque at the molecular level 5 . Transfer of a functional gene into arterial wall cells, termed arterial gene therapy, may be used to replace or palliate a defective gene, or to w x express a protein with a therapeutic effect 6 .
Effective arterial gene therapy requires techniques to Ž . Ž . introduce transfect a foreign gene transgene into the cells of the arterial wall. These techniques rely on transfer vectors which facilitate cellular penetration and intra-cellular trafficking of the transgene, as well as local delivery systems, either catheter-based or surgical, to deliver the vector to the vicinity of the target cells.
( )transgene in their genome and loose their replicative activ-Ž ity. Some of them retroviruses, lentiviruses and possibly . adeno-associated viruses are the only methods ensuring stable integration of transferred DNA into the chromosomal DNA of the target cell. In order to transform viruses into safe vectors, genomic sequences which are required for viral replication have been deleted.
RetroÕiral Õectors
These are single-stranded RNA viruses that bind to a specific cell surface receptor to get entry into the cell. Their capsid is surrounded by an envelope, the proteins of which mediate adhesion to the cell membrane. Following penetration into the cell, viral RNA is transformed into double-stranded DNA by the reverse transcriptase and the DNA integrates randomly into the host cell genome, creating a 'provirus'. The viral genome contains 3 structure genes, gag, pol and enÕ, encoding the capsid proteins, the reverse transcriptase and the envelope proteins respectively. The genome also contains assembly sequences, including the C gene, required for virion encapsidation. w x The retroviral vectors currently used 7 are derived from the Moloney murine leukemia virus. Schematically, in these vectors, the gag, pol and enÕ genes have been deleted and replaced, by homologous recombination, by the transgene, while the C sequence is retained. Due to packaging limitations, the size of the transgene in retroviral vectors is limited to 9 kb. In the absence of structure genes, these defective recombinant vectors are unable to replicate. In order to obtain viral stocks, it is therefore required to use 'packaging' cell lines, in which the gag, pol and enÕ genes are stably expressed. Transfection of these cells by the defective retroviruses genome leads to transcomplementation of the retroviral genome and to the production of replication-defective retroviral vectors harboring the transgene.
Since the retroviral genome integrates into cell DNA, the transgene is transmitted to daughter cells and its expression remains stable. Therefore, retroviral vectors have w x been used extensively for gene transfer in general 8 , and were the first vectors to be used for arterial gene transfer w x in particular 9-11 . Transfer is restricted to cells possessing the retroviral specific receptor. The receptors for both amphotropic, i.e., with extended tropism including human cells, and ecotropic, i.e., specific for murine cells, retrow x viruses have been cloned and are broadly expressed 12 . There are however, several problems associated with the Ž . use of retroviral vectors for arterial gene transfer: 1 w x retroviral vectors can only infect replicating cells 13 , which represent only a few percents of vascular cells in normal or atherosclerotic arteries, even following balloon w x Ž . angioplasty 14,15 ; 2 it is difficult to purify and concentrate these vectors in order to achieve the high titer solu-Ž . tions required for efficient gene transfer; 3 retroviral vectors are unstable and, therefore, inappropriate for in Ž . vivo gene transfer; 4 finally, integration of the retroviral genome into the host cell DNA carries potential risks of insertional mutagenesis as well as activation of cellular oncogenes following integration, which would argue for the restriction of retroviral vectors to the treatment of life-threatening diseases.
Retroviral vectors remain largely used in current gene therapy protocols, especially when the therapeutic gene is Ž . delivered ex vivo indirect gene transfer in proliferating cells which are subsequently transplanted back into the w x body 8 . However, they are poorly suited to in vivo gene Ž . transfer direct gene transfer . Recent developments in the field of retroviral vectors include engineering of lentiviral vectors based on HIV, which have been shown to achieve w x stable in vivo gene transfer into non-dividing cells 16 , as w x well as high titers pseudotyped vectors 17 . Whether these approaches will make retroviral vectors more effective and safe for clinical application however remains to be demonstrated.
AdenoÕiral Õectors
Ž w x. Adenoviruses for reviews, see Refs. 18-20 are nonenveloped viruses carrying a 36 kb double-stranded DNA. There are nearly 50 adenoviral serotypes, but only serotypes 2 and 5 have been used for gene transfer. Adenoviral genome is composed of regions which are expressed 'early' Ž . Ž . E1-E4 or 'late' L1-L5 relative to viral DNA replication. The expression of adenoviral genes is controlled by cellular transcription factors and by the E1 region which encodes a transactivating factor. Adenoviruses enter the cell through a receptor-mediated endocytosis pathway. Adenoviral particles bind to two receptor-types, including a glycoproteic receptor specific for the adenovirus fiber Ž . protein and surface integrins a b and a b that serve v 3 v 5 as receptors for the adenovirus penton protein, and are then internalized by endocytosis. Acidification of the endosomal content results in conformational changes of the viral capsid proteins, which leads to rupture of the endosomal vesicle and liberation of the viral DNA in the cytoplasm, before DNA degradation by lysosomal enzymes. Viral DNA is then transported from the cytoplasm into the transduced cell nucleus, where it remains episomal. Endosomolysis is a key feature of adenoviruses which is largely responsible for the high transfection efficiencies reported w x with adenoviral vectors in numerous organs 21-26 .
First generation recombinant adenoviral vectors cur-Ž w x. rently used for a review, see 27 are obtained through homologous recombination between the genome of a serotype 5 or 2 adenovirus, which has been deleted of its leftward part, and a shuttle plasmid in which the transgene has been inserted along with the leftward part of the adenoviral genome, in order to facilitate recombination Ž . Fig. 1 . Expression of the transgene is usually driven by a 'strong' viral promoter, such as the Rous sarcoma virus Ž . long terminal repeat RSV LTR , the cytomegalovirus Ž . CMV immediate-early promoterrenhancer, or the major late promoter and tripartite leader of adenovirus 2 or 5. These are constitutive promoters, which therefore lead to synthesis of large amounts of recombinant protein, but lack tissue specificity and allow no regulation once the gene is transferred. The vectors are made replication-defective by deletion of the E1A and E1B sequences from the viral genome. The E3 sequence is also deleted in order to Ž . accommodate insertion of long transgenes up to 7.5 kb . Homologous recombination as well as propagation of recombinant adenoviral vectors are achieved by co-transfection in 293 cells, a complementing cell line which constitutively expresses the E1 gene.
Adenoviral vectors allow to circumvent some of the Ž . problems encountered with retroviruses: 1 they can infect Ž . quiescent as well as replicating cells; 2 high titer stocks can be produced easily, generally ranging from 10 11 to 12 Ž . Ž . 10 plaque forming units pfu rml; 3 transfection effiw x ciencies of 100%, for endothelial cells 28 and ; 5%, for w x medial smooth muscle cells 29,30 , have been recently Ž . reported in animal models of arterial gene transfer; and 4 after infection, the adenovirus genome remains episomal, therefore avoiding the risk of insertional mutagenesis.
Nevertheless, several drawbacks of adenoviral vectors have been identified. First, current adenovectors are associated with only transient, 2-to 4-week, transgene expresw x Ž . sion 31 . Second, at a high multiplicity of infection MOI -i.e., the ratio of infectant viral particles to target cells -replication may be observed in E1-deleted adenoviral particles. This may be related to the presence of proteins w x with E1A-like activity in host cells 32 . Alternatively, Ž . replication competent adenovirus RCA may emerge during production of E1-deleted viral stocks through homologous recombination between the transgene and the E1 region of 293 cells. Third, it has been demonstrated that first-generation adenovectors evoke a strong cellular immune response, targeted at viral proteins as well as certain w x transgene products 33,34 , resulting in destruction of these w x cells by cytotoxic T lymphocytes 35 . In addition, infection of the target cells by adenoviral vectors leads to an acute inflammatory reaction, characterized by a neutrophilw x w x 36 and macrophage-rich 37 cellular infiltrate. Finally, it has been observed that local delivery of adenoviral vectors in normal arteries upregulates the expression of vascular cell adhesion molecules and may even trigger mild, alw x though significant, neointima formation 38 . The respective roles of the vector, the transgene, RCAs or impurities related to vector processing, in the generation of adverse effects associated with first-generation adenoviral vectors remain unclear.
The main consequences of the immunerinflammatory reaction directed against recombinant adenoviral vectors Ž are rapid extinction of transgene expression within a few . weeks and the occurrence of inflammatory reactions in the recipient. Repeated injections of adenoviral vectors w x might not result in prolonged transgene expression 39 due to a humoral immune response targeted at both viral w x proteins and transgene products 40 . Interestingly, the duration of transgene expression is substantially prolonged w x when transfer is achieved in newborn animals 41 , probably because these are not yet immunocompetent and can therefore tolerate viral proteins, or in animals in which cellular immune response has been pharmacologically dew x pressed 42 . Immunosuppression, however, cannot be used routinely in clinical practice. Thus, new adenoviral vectors, termed second and third-generation vectors, are currently w x developed 32,43,44 . These vectors are modified to prevent in a more efficient fashion residual expression of adenoviral proteins, thereby mitigating adenoviral proteinspecific cellular immune response, which in turn leads to less inflammatory reaction as well as protracted transgene expression. It must be borne in mind, however, that transgene expression is transient not only because of the cellular immune response, but also because of the episomal situation of the transgene, 'extinction' of promoter sequences and because of transcriptional and post-transcriptional mechanisms which remain largely unknown. In certain indications, however, such as prevention of restenosis, transient gene expression may be sufficient and may even confer a relative safety to adenoviral vector-based strategies for gene therapy, since potential deleterious effects related to transgene expression would be limited to a few weeks.
Other Õiral Õectors
Other viral vectors are being developed for gene transfer but have not been tested in models of arterial transfec-Ž . tion. The AAV adeno-associated viruses are singlestranded DNA parvoviruses. Wild-type AAV have the ability to integrate stably their genome into chromosome 19q13 of the human cellular genome. Such 'targeted' integration could theoretically limit the risk of insertional mutagenesis related to random integration into the host cell at Pennsylvania State University on http://cardiovascres.oxfordjournals.org/ Downloaded from ( )w x genome. However, recombinant AAV 45 do not appear to exhibit the same site specific integration as wild-type virus. Alternatively, herpes viruses would result in protracted transgene expression. They are however, toxic to the transfected cell, even in their replication-defective form w x 8 .
Non Õiral Õectors
The limitations and risks associated with viral vectors are powerful stimulants for the development of non viral vectors. DNA delivered by nonviral methods is maintained in an extra-chromosomal state and is not integrated into w x the cellular genome 46 .
Naked DNA
It is possible to incubate plasmid DNA with cells and obtain non-specific DNA uptake, which generally does not result in DNA integration into the host cell genome. When integration occurs, a rare phenomenon, it is random and carries a risk of insertional mutagenesis. Although this technique has a low efficiency of transfer, it is simple and safe. It is extremely well suited to ex-vivo transfer when transduced cells can be sorted using a selectable marker w x gene, but it has also been used clinically 47,48 .
Cationic liposomes
Cationic liposomes are positively charged artificial lipid vesicles, which incorporate negatively-charged plasmid DNA. In contrast with viral vectors, there is no size constraint for the transgene and preparation of the vectors Ž . is easy Fig. 2 . DNA-liposomes complexes contain an excess of liposomes and therefore of positive charges, which facilitate fusion between liposomes and the negaw x tively-charged cell membranes 49 . Once in the cytoplasm, most of the DNA-liposome complexes are degraded by lysosomal enzymes, and approximately 1% of the DNA which originally penetrated the cell enter the nucleus where it remains extra-chromosomal. This explains why transgene expression is transient when liposomes are used as vectors. Various cationic liposome preparations are Ž . commercially available: DOTMA-DOPE Lipofectin , Ž . DOSPArDOPE Lipofectamine , DC-cholesterol, DMRIErDOPE. The efficiency of cationic liposomes for gene transfer is superior to that of other non-viral methods and varies with the preparation used, the DNArliposome concentration ratio, the type and the proliferative status of the Ž transfected cells transfer appears increased in proliferating . cells . While in theory, under optimal conditions, in vitro transfection efficiencies can reach up to 90% of target cells, experience with in vivo arterial gene transfer sugw x gests that efficiency remains disturbingly low 50-52 . Compared to viral vectors these vectors are at least 3 logs less efficient, and require extremely high DNA concentrations to achieve successful gene transfer. Finally, cationic liposomes are potentially toxic due to the cellular accumulation of lipids. This untoward effect, however, has not been observed in several studies in which DNArliposomes w x complexes were introduced systemically 53 .
Conjugated Õectors
Ž w x. Conjugated vectors for a review, see 54 represent a heterogeneous class of vectors in which the transgene is Ž . conjugated to a polycation e.g., polylysine which is chemically bound to a proteic ligand. Polylysine forms a complex with negatively-charged DNA via electrostatic interaction, and condenses the DNA into a macromolecule-like structure. Binding of the ligand to its specific membrane receptor mediates vector internalization into the cell. Several studies have established that selective in vitro gene transfer can be achieved using this method. In these studies, the ligand was either an asialoglycoprotein, which is recognized by hepatocytes, or transferrin, which is recognized by many replicating cell lines, or polylysine-bound osidic residues. The main limit of this method is its poor efficiency, related to transgene degradation by lysosomal enzymes. Several methods have been used to improve somewhat transfection efficiency, such as Ž addition of chloroquine which prevents acidification of the endosomal content, thereby preventing transgene hy-. Ž drolysis or fusion peptides which disrupt the endosome . membrane and release the transgene into the cytoplasm . Such conjugated vectors have been used in vivo to obtain transient and partial correction of the hypercholesterolemia of Watanabe rabbits via transfer into hepatocytes of the w x gene encoding for the LDL receptor 55 .
( ) 2.3. Mixed Õectors Õiral r non Õiral
These vectors are designed to combine the benefits of both viral and non viral vectors.
Conjugated Õectors associated with defectiÕe adenoÕiruses
The combination of replication-defective adenoviruses and conjugated vectors is designed to increase gene trans- ) fer efficiency by using the adenovirus capability for endosomolysis, while retaining the specificity of transfer associated with ligandrmembrane receptor interactions. Several methods have been used. The most simple consists in incubating the target cells in the presence of a mixture of Ž . conjugated vectors e.g., DNA-polylysine-transferrin and defective adenoviruses. This method is 2000-fold more w x efficient than that using conjugated vectors alone 56 . Efficiency is even greater when defective adenoviruses are coupled to conjugated vectors via a monoclonal antibody w x targeted at the hexon protein of the adenoviral capsid 57 . In this case, however, transfer specificity is lost due to the interaction between the adenoviral fiber protein and its specific receptor. This problem has been solved by masking the fiber protein, either by a monoclonal antibody, or by oxidation of the fiber protein. These mixed conjugated vectors are very efficient in vitro. In contrast with recombinant adenoviral vectors, the size of the transgene is not a limiting factor, since it is not incorporated into the viral genome. However, in vivo efficiency of these vectors is limited by their instability and the requirement to cross the endothelial barrier in case of systemic injection. For this reason, mixed conjugated vectors are used in models of ex Ž . w x vivo indirect gene transfer 58 . Even under these 'optimal' conditions, duration of transgene expression is limited to approximately 2 weeks, probably because of non-integration of the transgene into the host cell genome and viral protein-specific immune response.
Conjugated Õectors associated with the Hemaggluti-( ) nating Virus of Japan HVJ
These vectors integrate liposomes, DNA and UV-inactivated HVJ particles. This combination has been proved effective in models of liver and kidney transfection, probably due to the ability of HVJ virus particles to penetrate the cell. It is assumed that when one HVJ particle gains access to the cell, via a specific receptor-mediated pathway, one or several liposomerDNA complexes are internalized in the cell and a certain amount of internalized DNA reaches the nucleus where it is expressed. The absence of toxicity of these vectors and their efficiency Ž . ; 10-fold that of cationic liposomes for vascular smooth muscle cell transfection, make them an attractive tool for w x arterial gene transfer 59 . These vectors have been used Ž for a host of cardiovascular applications for a review, see w x. 60 , including the study of the effect of autocrine-Ž paracrine vasoactive modulators e.g., the renin-angioten-
.
Gene delivery techniques

Percutaneous local deliÕery systems
Most potential targets of arterial gene therapy would require local expression of the transgene at a specific arterial site. This can be achieved either by delivering the gene vector in the vicinity of the target site, i.e., local delivery, or by incorporating in the vector design a ligand which will drive transgenic expression at that site, even if the vector is injected systemically. Advances in local gene delivery to the arterial wall have largely benefited from progress made in the technology of angioplasty balloon catheters. The simplest method for local arterial gene transfer is the 'dwell method', which requires to isolate surgically between two temporary ligatures an arterial segment, withdraw blood, inject into the isolated segment a solution containing the vector, then withdraw this solution after a variable incubation time and reestablish blood w x flow 28,65,66 . Dwelling allows to control several of the parameters which determine gene transfer efficiency: absence of leakage from the transfer compartment, minimization of vector loss in the systemic circulation, shortened transfer handling time, . . . , etc. The invasive nature of the 
Catheters
An 'ideal' local delivery catheter should incorporate the following features to perform optimal arterial gene transfer. First and foremost it should achieve very efficient gene transfer. Second, if it is intended to be used for prevention of restenosis, balloon angioplasty and gene transfer should be performed simultaneously during a one-step straightforward procedure using the same catheter. Third, the local delivery device should be safe, and, in particular, should not induce excessive injury to the arterial wall, in addition to the injury associated with the angioplasty per se. Fourth, gene delivery catheters should incorporate a perfusion design to limit myocardial ischemia during gene incubation. Finally, site-specificity is a key issue for arterial gene therapy. Local delivery catheters should be designed in order to minimize gene leakage in the bloodstream, which may limit local efficacy and result in systemic toxicity, especially when viral vectors are required.
Currently available local delivery catheters are listed in Table 1 . It must be stressed, however, that the vast majority of them have only been tested for arterial delivery of pharmacologic agents to normal arteries. Therefore, data obtained from the literature may not be directly applicable to gene delivery, in particular in atherosclerotic arteries. Schematically, local delivery through catheters involves 3 basic, device-related mechanisms: passive diffusion, pressure facilitation, and mechanical facilitation.
PassiÕe diffusion.
The double balloon catheter is made of two latex balloons which, when inflated into the target arterial segment, delineate a 'transfection chamber' Ž . of varying length usually 15 to 20 mm , into which the transfer vector can be instilled via an infusion port, generally using pressure. A retrieval port is usually available to withdraw the solution at the end of the incubation period. This catheter was the first to be used for catheter-based w x arterial gene transfer 10 . It has, however, several shortcomings. Passive diffusion of the gene vector requires long incubation times, which may generate tissue ischemia. There is a risk of vector diffusion into the systemic Ž circulation via side branches such side branches emerge . every 2-4 mm in the epicardial coronary arteries , which may result in both decreased transfer efficiency and viral dissemination. Finally, inflation of the two latex balloons is a source of additional arterial trauma both upstream and downstream of the transfected segment.
New catheters represent 'improved' designs of the double-balloon catheter. The Dispatche catheter is a sophisticated catheter allowing simultaneous distal perfusion and isolation of multiple infusion chambers between the w x catheter and the vessel wall 69 . The main advantage of this device is that even protracted incubations do not w x induce significant tissue ischemia 70 . This system has been successfully used to achieve substantial gene delivery into the endothelium and superficial medial layers of both w x normal and atherosclerotic rabbit arteries 71 . However, the infusion chambers do not ensure total isolation from the systemic circulation; therefore the Dispatche catheter, like most other local delivery catheters, is associated with a substantial risk of vector dissemination, in particular in the liver.
The hydrogel-coated balloon catheter is a conventional angioplasty balloon which is coated with a hydrophilic polymer which swells like a sponge in presence of a solution containing a drug or a gene vector. Upon inflation of the angioplasty balloon in the target vessel, the polymer express the adsorbed materials toward the arterial wall w x 72 . This balloon was initially designed to cross high-grade complex lesions. It turned out to be a very efficient local delivery system which has been released for clinical use in Europe and United States. This catheter is currently used for intracoronary delivery of urokinase during primary w x angioplasty for acute myocardial infarction 73 , and for local delivery of the VEGF cDNA in the peripheral arterw x ies of patients suffering end-stage arteriopathy 48 . Its main shortcoming is that during exposure of the catheter in the bloodstream, most of the hydrogel content is 'washed' w x off the balloon 69 . However, retention into the polymer may be enhanced by using a protective sheath.
Pressure facilitation. The Wolinsky catheter incor-
porates an angioplasty balloon with 25 mm diameter pores. During balloon angioplasty, inflation pressure drives the w x solution filling the balloon into the arterial wall 74 . However, at high inflation pressures typically required for Ž . optimal angioplasty 5 to 10 atm , porous balloons generate high velocity jets, which result in arterial perforation as well as reactive intimal hyperplasia, and carries a risk of gene dissemination. Therefore, improved porous balloon catheters have been designed to overcome these limitations, principally to dissociate balloon inflation pressure from vector instillation pressure. w x The microporous balloon catheter 75 incorporates an internal porous balloon, with 25 mm diameter pores, and a second external membrane with thousands of micropores of less than 1 mm diameter. These micropores tend to limit jetting and wall trauma.
Ž . The channeled balloon catheter Fig. 3 is a conventional angioplasty balloon covered with 24 longitudinal channels, each having a 100 mm diameter pore perfused via a separated lumen, allowing local low pressure instillaw x tion during high pressure balloon inflation 76 .
Mechanical facilitation.
The mechanism used to facilitate local delivery may be either an electrical field, in he case of the iontophoretic catheter, or a physical injury to the vessel wall in the case of the needle catheter or the nipple balloon. The iontophoretic balloon is a porous balloon with an inner electrode which serves as a cathode. An anode is applied on the skin. Electric current drives negatively-charged molecules outside of the balloon into w x the arterial wall 77 . This system appears particularly well suited to deliver negatively-charged plasmid DNA in the arterial wall.
Intracoronary stents
Clinical use of metallic intracoronary stents has become standard practice during routine PTCA to treat established coronary dissection. Intracoronary stents such as the Palmaz-Schatz stent have led to a reduction in the incidence of restenosis compared to conventional balloon angioplasty, most likely due to a reduction of acute and chronic constrictive remodeling of the vessel wall as well as an w x optimization of the initial geometric result of PTCA 78,79 .
In addition, intracoronary stents may be used as vehicles for local delivery of drugs or gene vectors into the Ž w x. arterial wall for reviews see 68, 80 . One of the approaches would be to coat the stent struts with endothelial cells, previously transfected with a therapeutic gene, the product of which may be released locally to exert therapeutic effects. In vitro experiments with metallic stents w x w x seeded with normal 81 , immortalized 82 , or tPA-transw x fected 83,84 endothelial cells have established the feasibility of this technique. However, clinical applicability of this technique remains limited due to the requirement of previous isolation and in vitro transfection of endothelial cells -a long and costly procedure -as well as the poor adhesion of these cells to the stent struts following expansion under flow condition. Another strategy is to use polymer-coated stents, which may act as a reservoir for a w x gene vector 85 , or even biodegradable polymeric stents w x 86 .
Polymers
The 'ideal' polymer for arterial gene transfer should contain large concentrations of genetic materials to ensure local delivery and protracted residence of the latter into the arterial wall. It should also be biocompatible for the bloodrwall interface, and, if possible, biodegradable. Biodegradable polymers could be used for arterial gene transfer in the form of intracoronary stents, micro-or w x nano-particles injected locally via a catheter 87 , gels Ž . 'pavement' coating the endoluminal aspect of the artery w x w x 88 , or periadventitial wrapping 89 . The latter method w x has been used to transfer plasmidic DNA 90 as well as w x antisense oligonucleotides 91 into the rat carotid artery, in order to prevent intimal thickening following arterial injury. In addition, we recently demonstrated that co-delivery of adenoviral vectors together with the block copolymer poloxamer 407 facilitates arterial transfection and w x allows for shorter incubation times 37 . 
Myocardial deliÕery
. matory responses and by the need for direct access to the myocardium which requires intraoperative, pericardial or perimyocardial injections. Alternatively, at least three studies have reported efficient transfection of the myocardium after intracoronary catheter delivery of adenoviral vectors w x 97-99 . Pressure conditions during delivery as well as pretreatment of the vessel with various vasoactive agents may impact heavily on the feasibility of myocardial gene w x transfer via the intracoronary route 99 .
Arterial gene transfer: Feasibility and problems
Two strategies can be used for gene transfer: indirect gene transfer involves in vitro transfection of vascular cells which are then implanted back into the vasculature; conversely, direct gene transfer is the direct introduction of a Ž . foreign gene into the arterial wall in vivo Fig. 4 . 
Indirect gene transfer
In their seminal experiments, Nabel et al. used recombinant retroviral vectors to transfer the b-galactosidase rew x porter gene into porcine endothelial cells in vitro 9 . After staining with the specific chromagen X-gal, transfected endothelial cells could be easily recognized and selected for subsequent introduction into the iliac artery in vivo using a double-balloon catheter. Expression of the transgene was found in these arteries several weeks after transfer. A similar strategy was successfully applied to in vitro w x transfected smooth muscle cells 11 . Other techniques for indirect gene transfer were later suggested such as seeding of genetically modified endothelial cells on the surface of w x endovascular metallic stents 83,84 , of Dacron arterial Ž . 
to arterial delivery. However, it is only suitable for autologous transfection, i.e., transfected cells can be transplanted only in the same patient from who these cells have been harvested. Moreover, it requires cell isolation and culture prior to transfer, which makes it a cumbersome and costly technique for routine clinical apw x plication 5,8 , with the exception of ex vivo transfer into saphenous vein grafts during coronary artery bypass surgery, for which the tissue to be transfected is readily available for ex vivo transfer.
Direct gene transfer
Direct gene transfer is a one-step method in which the transgene incorporated in a vector is directly delivered into the target arterial site. Again, Nabel et al. were the first to achieve direct arterial gene transfer using replication-defective retroviral vectors and cationic liposomes expressing the LacZ reporter gene, introduced via a double balloon w x catheter into porcine iliac arteries 10 . b-galactosidase activity was observed in all the transfected animals, up to 21 weeks in those animals transfected using retroviral vectors and 6 weeks when liposomes were used. Other w x studies using retroviral vectors 102 , cationic liposomes w x w x 50-52 or plasmid DNA 103,104 , have confirmed these results. However, in all theses studies transfection efficiency was far below 0.1% when nuclear-specific b-Ž galactosidase was used as reporter gene allowing discrimination from endogenous cytoplasmic b-galactosidase ac-. tivity .
Low transfection efficiency is a major limitation of these methods, in particular when the transgene encodes a protein which remains intracellular, a frequent feature for many of the candidate genes used in attempts to prevent w x restenosis 6 . Conversely, when the transgene encodes a w x secreted protein, such as the growth hormone 105 or a w x secreted growth factor 106,107 , a substantial biological effect may be observed even when a small number of target cells express the transgene.
Replication-defective adenoviral vectors have been used for gene transfer into the arterial wall, using surgical w x w x 28,36,37,65,66,108-111 or percutaneous 29,30,112-116 transfer techniques. The first generation vectors used in these experiments were replication defective due to deletion of the E1 sequence. When such a vector expressing nuclear-targeted b-galactosidase is delivered in contact with the endothelial layer without previous injury, for example using a surgical 'dwell' method or a double balloon catheter, transfer is strictly localized to the en-Ž . w x dothelium Fig. 5 29,111,115 . In addition, as previously mentioned, expression of the transgene is confined to the first days or weeks following delivery. Transfection efficiency is related to the concentration of the adenovirus at Pennsylvania State University on http://cardiovascres.oxfordjournals.org/ Downloaded from ( )w x stocks used 111 : efficiency increases with viral concentration when the latter remains F 5 P 10 10 pfurml; it then reaches a plateau, related to direct cytotoxicity of the vector. The magnitude and mechanism of this cytotoxic effect appear to vary with vector design and preparation. When concentration is further increased beyond 10 11 pfurml, efficiency decreases. Under certain conditions, however, transfection efficiency approximates 100% w x 28,29 . In intact vessels, the endothelium is therefore the elective target of replication-defective adenoviral vectors.
When adenovirus-mediated gene transfer is attempted following abrasion of the endothelial layer, transgene expression is found mostly in smooth muscle cells located in Ž . the superficial layers of the media tial clinical applications relate to atheromatous arteries. Methods to circumvent low transfer efficiency include the use of therapeutic genes encoding for secreted proteins, which may therefore affect not only transduced but also w x neighboring untransduced cells 6 . Alternatively, transfection efficiency can be enhanced by using adjunctive agents such as elastase, to permeate the internal elastic lamina w x w x 117 , or polymers such as poloxamer 407 37,120 .
The delivery device used has also a major impact on the risk of systemic dissemination of viral particles, which is high in the case of amphotropic adenoviral vectors. This may be explored by studying expression of the transgene, Ž . or rather its presence by PCR in organs remote from the transfer site. Pervious studies have shown that the risk is low when adenoviral vectors are introduced into a surgiw x cally isolated arterial segment 28,37 . When percutaneous delivery is attempted, however, the risk of viral dissemination becomes substantial, most of extra-arterial transfection w x being located in the liver 29,37 . The risk is high with the w x double balloon catheter 29 , the porous balloon catheter w x w x 121 , or the dispatch catheter 71 . It is reduced with the w x channeled balloon catheter 30 , and appears low with hydrogel balloon catheters, at least when a protective w x sheath is used 29 . The risk is also correlated to the degree of arterial trauma induced by the gene delivery device w x 114 . Other factors may promote viral spreading such as the use of non-specific viral promoters, high viral titers, as well as the presence of developed vasa vasora in the arterial wall, a typical feature of the atherosclerotic plaque.
Another issue is that in most of currently available transfection systems transgene expression cannot be regu- lated by physiological or exogeneous signals, which may represent an important limitation for clinical application of gene therapy to some diseases in which precise control over the level of protein production is required to achieve a therapeutic effect andror prevent toxicity. Several approaches have been tested in transgenic animals and in models of somatic gene transfer to regulate transgene w x expression 122-124 . The basic element of any system is a pharmacologic agent that modifies the activity of a transcription factor, which is capable of regulating a heterologous promoter that drives transgene expression. For exemple, Bohl et al. have recently designed a system in which two genes packaged into distinct retroviral vectors are transferred in primary myoblasts in vitro: an erythropoietin cDNA driven by a tetO-CMV promoter and a Ž . reverse transactivator rtTA . When doxycycline is added, rtTA binds the tetO-CMV promoter and activates tranw x scription of the erythropoietin cDNA 124 . To date, none of these systems have been tested in models of cardiovascular gene transfer. However, tight regulation of transgene expression may not be as crucial in cardiology as in Ž . inheritable metabolic diseases see below .
Conclusions and perspectives of clinical application
In vivo transfection of foreign genes in the cardiovascular system has broad applications. Retroviral vectors w x have been used to study cardivoascular development 125 and to learn more on the role of growth factors in the w x pathophysiology of intimal hyperplasia 106 . Clinical use of transfection techniques to treat cardiovascular disease w x represents a more challenging issue 5 .In vivo application of gene therapy requires a unique combination of appropriate vector, delivery system, target cell and therapeutic gene which is likely to be specifically tailored to each application. Therefore, there is no 'best' vector or delivery system. In fact, efforts should be focused on designing the appropriate combination required to approach each clinical situation, which should be tested in the appropriate experiw x mental models 126,127 . Current indications for arterial Ž . gene therapy should fulfill the following requirements: 1 it should be a disease without proven efficient conven-Ž tional therapy due to either ineffectiveness or major ad-. Ž . verse effects ; 2 the arterial lesions to be treated should Ž . be amenable to local delivery techniques; 3 pathophysiology should be clear enough for identification of candidate therapeutic genes.
There are currently two major potential indications for arterial gene therapy: prevention of restenosis after angioplasty and therapeutic angiogenesis to treat chronic is-Ž chemia, either in the myocardium or in the limbs for w x . reviews, see 5,6,47,128 . Other potential indications are prevention of degeneration of aortocoronary saphenous w x vein bypass grafts 101 and atheromatous plaque stabilizaw x tion 129 , but nearly all vascular diseases are theoretically w x amenable to gene therapy 4,130 , as well as a host of non vascular diseases in which arterial access to the diseased organs is available for local genetic treatment.
Genetic prevention of restenosis best exemplifies the importance of gene delivery techniques in achieving therapeutic success. Indeed, it has long been considered that restenosis -i.e., the recurrence of luminal narrowing in the months following angioplasty -results almost exclusively from intimal hyperplasia, a proliferating process involving medial and intimal layers of vascular smooth w x muscle cells 131 . Therefore, most of current strategies aimed at preventing restenosis by gene therapy consist in local transluminal delivery of antiproliferative genes in the abluminal arterial smooth muscle cells in order to inhibit w x intimal hyperplasia 5,128 . However, recent advances in the understanding of the pathophysiology of restenosis w x w x 132 indicate that, both in experimental models 133 and w x Ž in humans 134 , chronic constrictive remodeling or the . absence of compensatory vessel enlargement plays a major role in late luminal loss and that lumen diameter is strongly correlated to the magnitude of constriction but not to intimal thickness. The mechanism of constrictive rew x modeling, although still unclear 135 , may involve biological changes in the adventitia including inflammation, myw ocellular proliferation and migration, and fibrosis 136-x 138 . Should constrictive remodeling become a target for antiproliferative gene therapy, maybe periadventitial gene delivery will be more appropriate than current intraluminal delivery techniques. Adventitial transfection, however, is likely to induce unacceptable arterial trauma which may outweigh the potential benefit of the therapy. Alternatively, endovascular stents are both efficient and safe to prevent arterial constriction. It has been convincingly demonstrated that in-stent restenosis, which occurs in w x roughly 25% of the patients 78,79 , is almost exclusively w x composed of intimal hyperplasia 139 . Based on these recent data, the concept of integrated strategies to prevent restenosis arose, in which anti-remodeling stents are combined with antiproliferative genes to achieve optimal prew x vention of restenosis 140 . If integrated strategies are to be applied to the prevention of restenosis, we should consider developing in-stent gene delivery techniques as a priority. In this regard, preliminary results from a study by Van Belle et al. suggesting that efficient in-stent transfection w x can be performed percutaneously are encouraging 141 . 
